Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use

- Patients ≥18 and <75 years of age that meet the American College of Rheumatology (ACR) criteria for RA. - Patients with active RA defined as: 1. ≥3 tender joints and ≥3 swollen joints, or 2. DAS 28 score >3.1 - Patients who are discontinuing treatment with either infliximab or etanercept due to: 1. Lack of efficacy, or 2. Incomplete response. - Patients that, in the opinion of the physician could result beneficiated with the locally approved treatment scheme of adalimumab - Those patients who switch from infliximab or etanercept to adalimumab has been done in the last 60 days could be included in the study.

The following patients will not be included in the study: - Patients who have active infections. - Patients with latent TB. For this protocol, evidence of latent TB infection is defined as an induration (not erythema) of 5 mm or greater, 48-72 hrs after placement. Any suggested data on the clinical history or chest x-ray. - Patients participating into another study or clinical trial - Any condition that according to the criteria of the participating physician represents an obstacle for study conduct and/or represents a potential unacceptable risk for patients.